Cytotoxic effects of streptolysin o and streptolysin s enhance the virulence of poorly encapsulated group a streptococci.
Although the toxicity of streptolysin O (SLO) and streptolysin S (SLS) in purified group A streptococci (GAS) has been established, the effect of these molecules in natural infection is not well understood. To identify whether biologically relevant concentrations of SLO and SLS were cytotoxic to epithelial and phagocytic cells that the bacteria would typically encounter during human infection and to characterize the influence of cell injury on bacterial pathogenesis, we derived GAS strains deficient in SLO or SLS in the background of an invasive GAS M3 isolate and determined their virulence in in vitro and in vivo models of human disease. Whereas bacterial production of SLO resulted in lysis of both human keratinocytes and polymorphonuclear leukocytes, GAS expression of SLS was associated only with keratinocyte injury. Expression of SLO but not SLS impaired polymorphonuclear leukocyte killing of GAS in vitro, but this effect could only be demonstrated in the background of acapsular organisms. In mouse invasive soft-tissue infection, neither SLO or SLS expression significantly influenced mouse survival. By contrast, in a mouse model of bacterial sepsis after intraperitoneal inoculation of GAS, SLO expression enhanced the virulence of both encapsulated and acapsular GAS, whereas SLS expression increased the virulence only of acapsular GAS. We conclude that the cytotoxic effects of SLO protect GAS from phagocytic killing and enhance bacterial virulence, particularly of strains that may be relatively deficient in hyaluronic acid capsule. Compared to SLO, SLS in this strain background has a more modest influence on GAS pathogenicity and the effect does not appear to involve bacterial resistance to phagocytosis.
Sierig
Gabriele
G
Channing Laboratory and Division of Infectious Diseases, Brigham and Women's Hospital, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA.
Cywes
Colette
C
Wessels
Michael R
MR
Ashbaugh
Cameron D
CD
D000818:Animals; D016667:Bacterial Capsules / Q000378:metabolism; D001426:Bacterial Proteins; D005260:Female; D017353:Gene Deletion; D006461:Hemolysis; D006801:Humans; D015603:Keratinocytes; D051379:Mice; D009504:Neutrophils / Q000276:immunology; D010587:Phagocytosis; D018805:Sepsis / Q000382:microbiology / Q000401:mortality; D018461:Soft Tissue Infections / Q000382:microbiology / Q000401:mortality; D013290:Streptococcal Infections / Q000382:microbiology / Q000401:mortality; D013297:Streptococcus pyogenes / Q000378:metabolism / Q000472:pathogenicity*; D013301:Streptolysins / Q000235:genetics / Q000633:toxicity*; D014774:Virulence
D001426:Bacterial Proteins; D013301:Streptolysins; C025964:streptolysin O; C026050:streptolysin S